Business Context and Reporting Period
This Form 8-K Current Report was filed by NanoVibronix, Inc. (trading symbol: NAOV) on August 24, 2020. The registrant is an emerging growth company incorporated in Delaware. The filing primarily reports the entry into a material definitive agreement regarding an equity offering.
Key Financial Metrics and Transaction Details
- Transaction Type: Upsized firm commitment underwriting agreement for common stock.
- Underwriter: H.C. Wainwright & Co., LLC.
- Shares Sold: 4,531,434 shares of Common Stock (4,333,334 base shares plus 198,100 shares from partial option exercise).
- Offering Price: $0.75 per share to the public.
- Net Proceeds: Approximately $2.7 million after deducting underwriting discounts, commissions, and estimated offering expenses.
- Use of Proceeds: Working capital, general corporate purposes, and transitioning product manufacturing from China to the United States.
- Underwriting Costs: 7.5% underwriting discount, 1% management fee, and reimbursement for expenses (up to $100,000 legal fees, $12,900 clearing, and $50,000 non-accountable allowance).
- Warrants Issued: 339,858 warrants to the underwriter (7.5% of shares placed) with a 5-year term and an exercise price of $0.9375 per share.
Material Changes
The filing details a significant capital raise event. The company upsized the offering and partially exercised the underwriter's option to purchase additional shares. This transaction represents a material change in the company's capital structure and liquidity position, providing immediate cash inflow to support operations and strategic manufacturing relocation.
Outlook, Risks, and Contingencies
Management Commentary: The company intends to utilize the net proceeds specifically to transition manufacturing operations from China to the United States, alongside general working capital needs.
Closing Conditions: The offering was expected to close on August 27, 2020, subject to customary closing conditions.
Unregistered Securities: The Wainwright Warrants and shares issuable upon their exercise are not registered under the Securities Act of 1933 and are issued in reliance on Section 4(a)(2) and Regulation D exemptions.
Risks: The filing notes that the description of the Underwriting Agreement is qualified by reference to the full text of the agreement and warrant form attached as exhibits.
Investor Verification Checklist
- Verify the final closing date of the offering (expected August 27, 2020) and confirmation of the exact net proceeds received.
- Review the full text of the Underwriting Agreement (Exhibit 1.1) for specific covenants and indemnification provisions.
- Confirm the status of the manufacturing transition from China to the U.S. as a primary use of funds.
- Monitor the exercise of the remaining underwriter option (up to 451,900 shares) and the impact of the 339,858 warrants on future dilution.
- Check subsequent filings for any changes to the company's liquidity position or capital structure following this transaction.